Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why Submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research

User menu

  • My alerts

Search

  • Advanced search
Life Science Alliance
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research
  • My alerts
Life Science Alliance

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why Submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Follow lsa Template on Twitter
Research Article
Transparent Process
Open Access

G-CSF shifts erythropoiesis from bone marrow into spleen in the setting of systemic inflammation

Weiqiang Jing, Xing Guo, Fei Qin, Yue Li, Ganyu Wang, Yuxuan Bi, Xing Jin, Lihui Han, Xiaoyuan Dong, View ORCID ProfileYunxue Zhao  Correspondence email
Weiqiang Jing
1Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xing Guo
1Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fei Qin
1Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yue Li
1Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ganyu Wang
1Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuxuan Bi
1Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xing Jin
1Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lihui Han
2Department of Immunology, Shandong Key Laboratory of Infection and Immunity, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoyuan Dong
3Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yunxue Zhao
1Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
2Department of Immunology, Shandong Key Laboratory of Infection and Immunity, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yunxue Zhao
  • For correspondence: zhaoyunxue@sdu.edu.cn
Published 24 November 2020. DOI: 10.26508/lsa.202000737
  • Article
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1. BM erythropoiesis is gradually inhibited in G-CSF–treated mice.

    (A) Representative images of femurs from control and G-CSF–treated mice (scale bar = 1 cm). (B) Quantification of total BM cells. (C) Representative flow cytometric plots of CD71+Ter119+ cells in the BMs of control and G-CSF–treated mice. (D) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the BMs of control and G-CSF-treated mice. (E) Representative flow cytometric profiles of Ter119-APC and thiazole orange-stained cells from the BMs of control and G-CSF–treated mice. (F) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the BM of mice. (G) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the BMs of mice. (H) Representative fields of burst-forming unit erythroid-derived colonies in BM cultures from control and G-CSF–treated mice (×100 magnification; scale bar = 200 μm). (I) Quantification of the number of burst-forming unit erythroid-derived colonies in BM cultures from control and G-CSF treated mice. (J, K) Flow cytometric analyses of GATA-1 expression in BM cells from control and G-CSF–treated mice. (J) Representative histograms. (K) Mean fluorescence intensities were graphed. (L) Representative images of femurs from control and G-CSF–treated mice (scale bar = 1 cm). (M) Quantification of total BM cells. (N) Representative flow cytometric plots of CD71+Ter119+ BM cells for each indicated group. (O) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the BMs of control and G-CSF–treated mice. (P) Representative flow cytometric profiles of BM cells stained with anti-Ter119 and thiazole orange for each indicated group. (Q) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the BM of mice. (R) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the BMs of mice. n = 5/group (A, B), n = 3/group (C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R). **P < 0.01, ***P < 0.001 versus controls. Data are from one experiment representative of three experiments.

  • Figure S1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S1. G-CSF withdrawal restores BM erythropoiesis and decreases splenic erythropoiesis in G-CSF–treated mice.

    G-CSF was administered to male C57BL/6 mice at 50 μg/kg for 9 d by twice-daily subcutaneous injections, and then was stopped for 3, 6, 9, 12, and 15 d. (A) Representative images of femurs from normal control mice, G-CSF–treated mice, and stopping treatment of mice with G-CSF (scale bar = 1 cm). (B) Quantification of total BM cells. (C) Representative flow cytometric plots of CD71+Ter119+ cells from the BMs of normal control mice, G-CSF–treated mice, and stopping treatment of mice with G-CSF. (D) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the BMs of normal control mice, G-CSF–treated mice, and stopping treatment of mice with G-CSF. (E) Representative flow cytometric profiles of Ter119-APC and thiazole orange–stained cells from the BMs of control mice, G-CSF–treated mice, and stopping treatment of mice with G-CSF. (F) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the BM of mice. (G) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the BMs of mice. (H) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control mice, G-CSF–treated mice, and stopping treatment of mice with G-CSF. (I) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of control mice, G-CSF–treated mice, and stopping treatment of mice with G-CSF. (J) Representative flow cytometric plots of Ter119-APC and thiazole orange–stained splenocytes from control mice, G-CSF–treated mice, and stopping treatment of mice with G-CSF. (K) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (L) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. n = 3/group (A, B, C, D, E, F, G, H, I, J, K, L). *P < 0.05, **P < 0.01, ***P < 0.001 versus controls, n.s., no significance.

  • Figure S2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S2. The effects of single dose of G-CSF (50 μg/kg) on BM and spleen.

    (A) Representative images of femurs from control and G-CSF–treated mice (scale bar = 1 cm). (B) Quantification of total BM cells. (C) Representative flow cytometric plots of CD71+Ter119+ cells in the BMs of control and G-CSF–treated mice. (D) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the BMs of control and G-CSF–treated mice. (E) Representative flow cytometric profiles of Ter119-APC and thiazole orange–stained cells from the BMs of control and G-CSF–treated mice. (F) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the BM of mice. (G) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the BMs of mice. (H) Representative flow cytometric plots of CD11b+Ly6G+ cells in the BMs of control and G-CSF–treated mice. (I) Flow cytometric quantification of CD11b+Ly6G+ neutrophils in the BMs of control and G-CSF–treated mice. (J) Flow cytometric quantification of CD11b+ neutrophils in the BMs of control and G-CSF–treated mice. (K) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control and G-CSF–treated mice. (L) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of control and G-CSF–treated mice. (M) Representative flow cytometric plots of Ter119-APC and thiazole orange–stained splenocytes from control and G-CSF–treated mice. (N) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (O) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. (P) Macroscopic views of spleens in control and G-CSF–treated mice (scale bar = 1 cm). (Q) Average weights of spleens in control and G-CSF–treated mice. (R) Total cell numbers of spleens in control and G-CSF–treated mice. (S) Compressive strength of spleens from each group. n = 3/group (A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S). *P < 0.05, **P < 0.01, ***P < 0.001.

  • Figure S3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S3. G-CSF treatment enhances granulopoiesis in the BM of mice.

    (A, B) Flow cytometric analysis of the BM neutrophils (CD11b+Ly6G+) in control and G-CSF–treated mice. (A) Representative flow cytometric plots of CD11b+Ly6G+ cells in the BMs of control and G-CSF–treated mice. (B) Flow cytometric quantification of CD11b+Ly6G+ neutrophils in the BMs of control and G-CSF–treated mice. (C) Peripheral neutrophil counts in control and G-CSF–treated mice. (D) Wright–Giemsa staining of BM cells from control and G-CSF–treated mice. Original magnification ×100 (upper panels); ×1,000 (lower panels) (E) Wright–Giemsa staining of peripheral blood cells from control and G-CSF–treated mice. (F) Representative fields of CFU-GM–derived colonies in BM cultures from control and G-CSF–treated mice (×100 magnification; scale bar = 200 μm). (G) Quantification of the number of CFU-GM–derived colonies in BM cultures from control and G-CSF treated mice. n = 5/group (A, B, C, D, E), n = 3/group (F, G).***P < 0.001.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2. G-CSF enhances splenic erythropoiesis in a dose- and time-dependent manner.

    (A) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control and G-CSF–treated mice. (B) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of control and G-CSF–treated mice. (C) Representative flow cytometric plots of Ter119-APC and thiazole orange-stained splenocytes from control and G-CSF–treated mice. (D) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (E) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. (F) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control and G-CSF–treated mice. (G) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of control and mice treated with G-CSF at different time points. (H) Representative flow cytometric profiles of splenocytes stained with anti-Ter119 and thiazole orange for each indicated group. (I) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (J) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. (K) Representative fields of burst-forming unit-erythroid-derived colonies in cultures of splenocytes from control and G-CSF-treated mice (×100 magnification; scale bar = 200 μm). (L) Quantification of burst-forming unit erythroid-derived colonies in cultures of splenocytes from control and G-CSF–treated mice. (M) GATA-1 expression of splenocyte was measured by flow cytometry, and the representative histograms were shown. (N) Bar graphs showing mean fluorescence intensities. (O) Peripheral blood hematologic parameters of sham-operated mice, splenectomized mice, sham-operated mice treated with G-CSF, and splenectomized mice treated with G-CSF. Red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), and reticulocytes (Retics). n = 3/group (A, B, C, D, E, F, G, H, I, J, K, L, M, N), n = 10/group (O). *P < 0.05, **P < 0.01, ***P < 0.001 versus controls. Data are from one experiment representative of three experiments.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3. Infection of mice with E. coli impairs BM erythropoiesis, enhances splenic erythropoiesis, and promotes BM granulopoiesis.

    (A) Representative images of femurs from control mice and E. coli–infected mice (scale bar = 1 cm). (B) Quantification of total BM cells. (C) Representative flow cytometric plots of CD71+Ter119+ cells in the BMs of control mice and E. coli–infected mice. (D) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the BMs of control and E. coli-infected mice. (E) Representative flow cytometric profiles of Ter119-APC and thiazole orange-stained cells from the BM of control mice and E. coli–infected mice. (F) Flow cytometric quantification of reticulocytes (Ter119+Thiazole orange+) in the BM of mice. (G) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the BMs of mice. (H) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control and E. coli-infected mice. (I) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of control and E. coli–infected mice. (J) Representative flow cytometric plots of Ter119-APC and thiazole orange–stained splenocytes from control and E. coli–infected mice. (K) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from control and E. coli–infected mice. (L) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from control and E. coli-infected mice. (M) Peripheral blood hematologic parameters of control mice and E. coli-infected mice. Red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), and reticulocytes (Retics). (N) Serum concentrations of G-CSF in control and E. coli–infected mice. (O) Representative flow cytometric plots of CD11b+Ly6G+ cells in the BMs of control and E. coli-infected mice. (P) Flow cytometric quantification of CD11b+Ly6G+ neutrophils in the BMs of control and E. coli–infected mice. (Q) Peripheral neutrophil counts in control and E. coli–infected mice. n = 5/group (A, B, M, Q), n = 3/group (C, D, E, F, G, H, I, J, K, L, N, O, P). **P < 0.01, ***P < 0.001.

  • Figure S4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S4. Treatment of mice with LPS impairs BM erythropoiesis, enhances splenic erythropoiesis, and promotes BM granulopoiesis.

    (A) Representative images of femurs from control and LPS-treated mice (scale bar = 1 cm). (B) Quantification of total BM cells. (C) Representative flow cytometric plots of CD71+Ter119+ cells in the BMs of control and LPS-treated mice. (D) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the BMs of control and LPS-treated mice. (E) Representative flow cytometric profiles of Ter119-APC and thiazole orange-stained cells from the BM of control and LPS-treated mice. (F) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the BM of mice. (G) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the BMs of mice. (H) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control and LPS-treated mice. (I) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of control and LPS-treated mice. (J) Representative flow cytometric profiles of Ter119-APC and thiazole orange-stained cells from the spleen of control and LPS-treated mice. (K) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from control and LPS-treated mice. (L) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from control and LPS-treated mice. (M) Peripheral blood hematologic parameters of control and LPS-treated mice. Red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), and reticulocytes (Retics). (N) Serum concentrations of G-CSF in control and LPS-treated mice. (O) Representative flow cytometric plots of CD11b+Ly6G+ cells in the BMs of control and LPS-treated mice. (P) Flow cytometric quantification of CD11b+Ly6G+ neutrophils in the BMs of control and LPS-treated mice. (Q) Peripheral neutrophil counts in control and LPS-treated mice. n = 5/group (A, B, M, Q), n = 3/group (C, D, E, F, G, H, I, J, K, L, N, O, P). **P < 0.01, ***P < 0.001.

  • Figure S5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S5. The effects of single treatment of LPS (0.5 mg/kg) on BM and spleen.

    (A) Representative images of femurs from control and LPS-treated mice (scale bar = 1 cm). (B) Quantification of total BM cells. (C) Representative flow cytometric plots of CD71+Ter119+ cells in the BMs of control and LPS-treated mice. (D) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the BMs of control and LPS-treated mice. (E) Representative flow cytometric profiles of Ter119-APC and thiazole orange-stained cells from the BMs of control and LPS-treated mice. (F) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the BM of mice. (G) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the BMs of mice. (H) Representative flow cytometric plots of CD11b+Ly6G+ cells in the BMs of control and LPS-treated mice. (I) Flow cytometric quantification of CD11b+Ly6G+ neutrophils in the BMs of control and LPS-treated mice. (J) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control and LPS-treated mice. (K) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of control and LPS-treated mice. (L) Representative flow cytometric plots of Ter119-APC and thiazole orange-stained splenocytes from control and LPS-treated mice. (M) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (N) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. (O) Macroscopic views of spleens in control and LPS-treated mice (scale bar = 1 cm). (P) Average weights of spleens in control and LPS-treated mice. (Q) Total cell numbers of spleens in control and LPS-treated mice. (R) Compressive strength of spleens from each group. n = 3/group (A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R). **P < 0.01, ***P < 0.001.

  • Figure S6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S6. The effects of single infection of E. coli (1 × 106) on BM and spleen.

    (A) Representative images of femurs from control and E. coli–infected mice (scale bar = 1 cm). (B) Quantification of total BM cells. (C) Representative flow cytometric plots of CD71+Ter119+ cells in the BMs of control and E. coli–infected mice. (D) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the BMs of control and E. coli–infected mice. (E) Representative flow cytometric profiles of Ter119-APC and thiazole orange–stained cells from the BMs of control and E. coli–infected mice. (F) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the BM of mice. (G) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the BMs of mice. (H) Representative flow cytometric plots of CD11b+Ly6G+ cells in the BMs of control and E. coli-infected mice. (I) Flow cytometric quantification of CD11b+Ly6G+ neutrophils in the BMs of control and E. coli–infected mice. (J) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control and E. coli–infected mice. (K) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of control and E. coli–infected mice. (L) Representative flow cytometric plots of Ter119-APC and thiazole orange–stained splenocytes from control and E. coli–infected mice. (M) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (N) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. (O) Macroscopic views of spleens in control and E. coli–infected mice (scale bar = 1 cm). (P) Average weights of spleens in control and E. coli–infected mice. (Q) Total cell numbers of spleens in control and E. coli-infected mice. (R) Compressive strength of spleens from each group. n = 3/group (A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R). *P < 0.05, **P < 0.01, ***P < 0.001.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4. G-CSF neutralization decreases BM granulopoiesis, restores BM erythropoiesis, and suppresses splenic erythropoiesis in LPS-treated mice.

    (A) Serum concentrations of G-CSF in control mice, LPS-treated mice, and LPS-treated mice with anti-G-CSF treatment. (B) Representative images of femurs from control mice, LPS-treated mice, and LPS-treated mice with anti-G-CSF treatment (scale bar = 1 cm). (C) Quantification of total BM cells. (D) Representative flow cytometric plots of CD71+Ter119+ cells in the BMs of control mice, LPS-treated mice, and LPS-treated mice with anti-G-CSF treatment. (E) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the BMs of control mice, LPS-treated mice, and LPS-treated mice with anti–G-CSF treatment. (F) Representative flow cytometric profiles of Ter119-APC and thiazole orange–stained cells from the BM of control mice, LPS-treated mice, and LPS-treated mice with anti–G-CSF treatment. (G) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the BM of mice. (H) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the BMs of mice. (I) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control mice, LPS-treated mice and LPS-treated mice with anti-G-CSF treatment. (J) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of control mice, LPS-treated mice, and LPS-treated mice with anti–G-CSF treatment. (K) Representative flow cytometric profiles of Ter119-APC and thiazole orange–stained cells from the spleen of control mice, LPS-treated mice, and LPS-treated mice with anti–G-CSF treatment. (L) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (M) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. (N) Representative flow cytometric plots of CD11b+Ly6G+ cells in the BMs of control mice, LPS-treated mice, and LPS-treated mice with anti–G-CSF treatment. (O) Flow cytometric quantification of CD11b+Ly6G+ neutrophils in the BMs of control mice, LPS-treated mice, and LPS-treated mice with anti–G-CSF treatment. (P) Peripheral neutrophil counts in control mice, LPS-treated mice, and LPS-treated mice with anti–G-CSF treatment. n = 3/group (D, E, F, G, H, I, J, K, L, M, N, O), n = 5/group (A, B, C, P). ***P < 0.001.

  • Figure S7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S7. Anti–G-CSF isotype control has no influence on BM and spleen that changed by LPS treatment.

    (A) Representative images of femurs from WT control mice, LPS-treated mice and LPS-treated mice with isotype treatment (scale bar = 1 cm). (B) Quantification of total BM cells. (C) Representative flow cytometric plots of CD71+Ter119+ cells in the BMs of control, LPS-treated mice, and LPS-treated mice with isotype treatment. (D) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the BMs of control, LPS-treated mice, and LPS-treated mice with isotype treatment. (E) Representative flow cytometric profiles of Ter119-APC and thiazole orange-stained cells from the BMs of control, LPS-treated mice, and LPS-treated mice with isotype treatment. (F) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the BM of mice. (G) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the BMs of mice. (H) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control, LPS-treated mice, and LPS-treated mice with isotype treatment. (I) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the spleens of control, LPS-treated mice, and LPS-treated mice with isotype treatment. (J) Representative flow cytometric profiles of Ter119-APC and thiazole orange–stained cells from the spleens of control, LPS-treated mice, and LPS-treated mice with isotype treatment. (K) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens of mice. (L) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens of mice. (M) Representative flow cytometric plots of CD11b+Ly6G+ cells in the BMs of control, LPS-treated mice, and LPS-treated mice with isotype treatment. (N) Flow cytometric quantification of CD11b+Ly6G+ cells in the BMs of mice. (O) Representative images of spleens from WT control mice, LPS-treated mice, and LPS-treated mice with isotype treatment. (P) Average weights of spleens from each group. (Q) Total cell numbers of spleens from each group. (R) Compressive strength of spleens from each group. n = 3/group (A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R). *P < 0.05, ***P < 0.001.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5. TLR4 knockout down-regulates G-CSF expression, abolishes the suppression of BM erythropoiesis, inhibits splenic erythropoiesis, and blocks emergency granulopoiesis in LPS-treated mice.

    (A) Representative images of femurs from WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS (scale bar = 1 cm). (B) Quantification of total BM cells. (C) Representative flow cytometric plots of CD71+Ter119+ cells in the BMs of WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS. (D) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the BMs of WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS. (E) Representative flow cytometric profiles of Ter119-APC and thiazole orange–stained cells from the BM of WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS. (F) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the BM of mice. (G) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the BMs of mice. (H) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS. (I) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of WT control mice, LPS-treated mice and TLR4−/− mice treated with LPS. (J) Representative flow cytometric profiles of Ter119-APC and thiazole orange-stained cells from the spleen of WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS. (K) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (L) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS. (M) Serum concentrations of G-CSF in WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS. (N) Representative flow cytometric plots of CD11b+Ly6G+ cells in the BMs of WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS. (O) Flow cytometric quantification of CD11b+Ly6G+ neutrophils in the BMs of WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS. (P) Peripheral neutrophil counts in WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS. n = 5/group (A, B, M, P), n = 3/group (C, D, E, F, G, H, I, J, K, L, N, O). ***P < 0.001.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6. EPO mediates G-CSF–induced splenic erythropoiesis.

    (A) Serum levels of EPO in control and G-CSF–treated mice. The mice were treated with G-CSF for 3 d. (B) Quantification of kidney EPO mRNA by quantitative reverse-transcribed polymerase chain reaction, normalized to β-actin mRNA. The mice were treated with G-CSF for 3 d. (C) Western blot analyses for the levels of HIF-1α and HIF-2α in kidneys. The mice were treated with G-CSF for 0, 1, 2, 3 d. Protein lysates were prepared from the kidney, and Western blot analyses were performed. (D) Protocol of anti-EPO blocking antibody treatment in G-CSF-treated mice. (E, F, G, H, I) Flow cytometric analysis of the splenic erythropoiesis in control mice, G-CSF–treated mice, and G-CSF–treated mice with anti-EPO treatment. (E) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens. (F) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens from different treatment groups. (G) Representative flow cytometric plots of Ter119-APC and thiazole orange-stained splenocytes from control mice, G-CSF–treated mice, and G-CSF–treated mice with anti-EPO treatment. (H) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (I) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. (J) Representative fields of burst-forming unit erythroid (BFU-E)–derived colonies in spleen cultures from control, G-CSF–treated mice, and G-CSF–treated mice with anti-EPO (×100 magnification; scale bar = 200 μm). (K) Quantification of the number of BFU-E-derived colonies in spleen cultures from different groups. (L) Protocol of red blood cell transfusions in G-CSF–treated mice. (M) Serum levels of EPO in WT control mice, G-CSF–treated mice, and G-CSF–treated mice with red blood cell transfusion. (N, O, P, Q, R) Flow cytometric analysis of the splenic erythropoiesis in control mice, G-CSF–treated mice, and G-CSF–treated mice with red blood cell transfusion. (N) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens. (O) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens from different treatment groups. (P) Representative flow cytometric profiles of splenocytes stained with anti-Ter119 and thiazole orange for each indicated group. (Q) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (R) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. (S) Representative fields of BFU-E–derived colonies in spleen cultures from control, G-CSF–treated mice, and G-CSF–treated mice with transfusion (×100 magnification; scale bar = 200 μm). (T) Quantification of the number of BFU-E–derived colonies in spleen cultures from different groups. n = 3/group (A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T). **P < 0.01, ***P < 0.001.

  • Figure S8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S8. EPO injections significantly enhance splenic erythropoiesis and induce mild splenomegaly.

    (A) Representative flow cytometric plots of CD71+Ter119+ cells in freshly isolated splenocytes from control and EPO-treated mice. (B) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of control and EPO-treated mice. (C) Representative flow cytometric profiles of Ter119-APC and thiazole orange–stained spleen cells from control and EPO-treated mice. (D) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (E) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. (F) Representative fields of burst-forming unit erythroid–derived colonies in spleen cultures from control and EPO-treated mice (×100 magnification; scale bar = 200 μm). (G) Quantification of the number of burst-forming unit erythroid–derived colonies in spleen cultures from control and EPO-treated mice. (H) Peripheral blood hematologic parameters of control and EPO-treated mice. Red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), and reticulocytes (Retics). (I) Representative photographs of spleens from control mice and EPO-treated mice. (J) Average weights of spleens from each group. (K) Total cell numbers of spleens from each group. (L) Compressive strength of spleens from each group. n = 5/group (A, B, C, D, E, I, J, K, L), n = 3/group (F, G), n = 7/group (H). *P < 0.05, **P < 0.01, ***P < 0.001.

  • Figure S9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S9. The effects of single dose of EPO (200 U/kg) on spleen.

    (A) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control and EPO-treated mice. (B) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens of control and EPO-treated mice. (C) Representative flow cytometric plots of Ter119-APC and thiazole orange-stained splenocytes from control and EPO-treated mice. (D) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (E) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. n = 3/group (A, B, C, D, E). *P < 0.05.

  • Figure S10.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S10. Anti-EPO isotype control has no influence on BM and spleen that changed by G-CSF treatment.

    (A) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens of control, G-CSF–treated mice, and G-CSF–treated mice with isotype treatment. (B) Flow cytometric quantification of CD71+Ter119+ erythroid cells in the spleens of control, G-CSF–treated mice, and G-CSF–treated mice with isotype treatment. (C) Representative flow cytometric profiles of Ter119-APC and thiazole orange–stained cells from the spleens of control, G-CSF–treated mice, and G-CSF–treated mice with isotype treatment. (D) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens of mice. (E) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens of mice. (F) Representative images of spleens from WT control mice, G-CSF–treated mice, and G-CSF–treated mice with isotype treatment (scale bar = 1 cm). (G) Average weights of spleens from each group. (H) Total cell numbers of spleens from each group. (I) Compressive strength of spleens from each group. n = 3/group (A, B, C, D, E, F, G, H, I). ***P < 0.001.

  • Figure S11.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S11. The kinetics of red blood cell numbers and hemoglobin levels in G-CSF–treated mice.

    (A) Peripheral red blood cell (RBC) counts in G-CSF–treated mice. (B) Peripheral hemoglobin (HGB) counts in G-CSF–treated mice. n = 6/group (A, B).

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7. Adenine intake–induced renal dysfunction decreases serum EPO levels and inhibits splenic erythropoiesis in G-CSF–treated mice.

    (A, B) Levels of blood urea nitrogen and serum creatinine in control mice, G-CSF–treated mice, and G-CSF–treated mice fed with adenine. (C) Representative histological photomicrographs of kidneys. Original magnification, top panels ×100, and bottom panels ×200. (D) Serum levels of EPO in control mice, G-CSF–treated mice, and G-CSF–treated mice fed with adenine. (E, F, G, H, I) Flow cytometric analysis of the splenic erythropoiesis in control mice, G-CSF–treated mice, G-CSF–treated mice fed with adenine and G-CSF–treated mice fed with adenine and with EPO treatment. (E) Representative flow cytometric plots of CD71+Ter119+ cells in the spleens. (F) Bar graphs showing quantification of CD71+Ter119+ cells in the spleens from different treatment groups. (G) Representative flow cytometric plots of Ter119-APC and thiazole orange–stained splenocytes from different treatment groups. (H) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the spleens from different treatment groups. (I) Flow cytometric quantification of erythroblasts (Ter119+ Thiazole orange++) in the spleens from different treatment groups. n = 3/group (A, B, C, D, E, F, G, H, I). **P < 0.01, ***P < 0.001, n.s., no significance.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8. G-CSF treatment leads to splenomegaly and increases splenic fragility in mice.

    (A) Macroscopic views of spleens in control and G-CSF–treated mice (scale bar = 1 cm). (B) Average weights of spleens in control and G-CSF–treated mice. (C) Total cell numbers of spleens in control and G-CSF–treated mice. (D) The ratios of spleen weight with respect to body weight. (E) Schema showing the compression test of spleen. (F) Compressive strength of spleens from each group. (G) Representative images of spleens from control and G-CSF-treated mice (scale bar = 1 cm). (H) Average weights of spleens from each group. (I) Total cell numbers of spleens from each group. (J) Compressive strength of spleens from each group. (K, M) Histopathological views of spleen tissues from the WT control mice and G-CSF–treated mice. Splenic sections were stained with H&E. The thickness of splenic capsule was measured under the microscope and the numbers of trabeculae were counted in histological photomicrographs. Original magnification, upper panels ×100 and lower panels ×200. (L) Quantification of thicknesses of splenic capsules. (N) Quantification of the numbers of trabecula in different groups (×100). n = 5/group (A, B, C, D, E, F, G, H, I, J, K, L, M, N). *P < 0.05, **P < 0.01, ***P < 0.001.

  • Figure S12.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S12. G-CSF treatment has no influence on the liver, lung, heart, kidney, and body weight.

    (A) Liver weights of control and G-CSF–treated mice. (B) Lung weights of control and G-CSF–treated mice. (C) Heart weights of control and G-CSF–treated mice. (D) Kidney weights of control and G-CSF–treated mice. (E) Body weights of control and G-CSF–treated mice. n = 5/group (A, B, C, D, E).

  • Figure S13.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S13. Either E. coli infection or LPS treatment induces splenomegaly and high fragility of spleen in mice.

    (A) Representative images of spleens from control mice and E. coli-infected mice (scale bar = 1 cm). (B) Representative images of spleens from control mice and LPS-treated mice (scale bar = 1 cm). (C) Average weights of spleens from control mice and E. coli–infected mice. (D) Average weights of spleens from control mice and LPS-treated mice. (E) Total cell numbers of spleens from control mice and E. coli–infected mice. (F) Total cell numbers of spleens from control mice and LPS-treated mice. (G) Compressive strength of spleens from control mice and E. coli–infected mice. (H) Compressive strength of spleens from control mice and LPS-treated mice. n = 5/group (A, B, C, D, E, F, G, H). ***P < 0.001.

  • Figure 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 9. TLR4-mediated G-CSF production contributes to splenomegaly and high fragility of spleen during systemic inflammation in mice.

    (A) Representative images of spleens from WT control mice, LPS-treated mice, and LPS-treated mice with anti–G-CSF treatment (scale bar = 1 cm). (B) Average weights of spleens from each group. (C) Total cell numbers of spleens from each group. (D) Compressive strength of spleens from each group. (E) Representative images of spleens from WT control mice, LPS-treated mice, and TLR4−/− mice treated with LPS (scale bar = 1 cm). (F) Average weights of spleens from each group. (G) Total cell numbers of spleens from each group. (H) Compressive strength of spleens from each group. n = 5/group (A, B, C, D, E, F, G, H). ***P < 0.001.

  • Figure 10.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 10. EPO neutralization, red blood cell transfusion, and adenine-induced kidney injury alleviate splenomegaly in G-CSF–treated mice.

    (A) Representative images of spleens from WT control mice, G-CSF–treated mice, and G-CSF–treated mice with anti-EPO treatment (scale bar = 1 cm). (B) Average weights of spleens from each group. (C) Total cell numbers of spleens from each group. (D) Compressive strength of spleens from each group. (E) Representative images of spleens from WT control mice, G-CSF–treated mice, and G-CSF–treated mice with red blood cell transfusion (scale bar = 1 cm). (F) Average weights of spleens from each group. (G) Total cell numbers of spleens from each group. (H) Compressive strength of spleens from each group. (I) Representative images of spleens from control mice, G-CSF–treated mice, G-CSF–treated mice fed with adenine, and G-CSF–treated mice fed with adenine and with EPO treatment (scale bar = 1 cm). (J) Average weights of spleens from each group. (K) Total cell numbers of spleens from each group. (L) Compressive strength of spleens from each group. n = 5/group (A, B, C, D, E, F, G, H, I, J, K, L). *P < 0.05, **P < 0.01, ***P < 0.001.

PreviousNext
Back to top
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
G-CSF shifts erythropoiesis from bone marrow into spleen in the setting of systemic inflammation
(Your Name) has sent you a message from Life Science Alliance
(Your Name) thought you would like to see the Life Science Alliance web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
G-CSF mediates splenic erythropoiesis in inflammation
Weiqiang Jing, Xing Guo, Fei Qin, Yue Li, Ganyu Wang, Yuxuan Bi, Xing Jin, Lihui Han, Xiaoyuan Dong, Yunxue Zhao
Life Science Alliance Nov 2020, 4 (1) e202000737; DOI: 10.26508/lsa.202000737

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
G-CSF mediates splenic erythropoiesis in inflammation
Weiqiang Jing, Xing Guo, Fei Qin, Yue Li, Ganyu Wang, Yuxuan Bi, Xing Jin, Lihui Han, Xiaoyuan Dong, Yunxue Zhao
Life Science Alliance Nov 2020, 4 (1) e202000737; DOI: 10.26508/lsa.202000737
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
Issue Cover

In this Issue

Volume 4, No. 1
January 2021
  • Table of Contents
  • Cover (PDF)
  • About the Cover
  • Masthead (PDF)
Advertisement

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Conclusions
    • Materials and Methods
    • Acknowledgements
    • References
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF

Subjects

  • Immunology
  • Microbiology, Virology & Host Pathogen Interaction

Related Articles

  • No related articles found.

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SorCS1 in amyloid-β synaptic pathology
  • The GET pathway acts in promoting mitophagy
  • Proximity to the SC promotes exchanges
Show more Research Article

Similar Articles

EMBO Press LogoRockefeller University Press LogoCold Spring Harbor Logo

Content

  • Home
  • Newest Articles
  • Current Issue
  • Archive
  • Subject Collections

For Authors

  • Submit a Manuscript
  • Author Guidelines
  • License, copyright, Fee

Other Services

  • Alerts
  • Twitter
  • RSS Feeds

More Information

  • Editors & Staff
  • Reviewer Guidelines
  • Feedback
  • Licensing and Reuse
  • Privacy Policy

ISSN: 2575-1077
© 2023 Life Science Alliance LLC

Life Science Alliance is registered as a trademark in the U.S. Patent and Trade Mark Office and in the European Union Intellectual Property Office.